Michael Crichton and Lymphoma: A Storyteller's Quiet Diagnosis

A diagnosis kept private

Michael Crichton, the physician-turned-novelist behind Jurassic Park and The Andromeda Strain and the creator of ER, died in November 2008 at the age of 66. NPR reported that he had been battling cancer.

His family's statement described his illness as "private and courageous," and remembered him as "a great storyteller who challenged our preconceived notions about the world around us." NPR's report did not name the type of cancer.

That gap is worth sitting with rather than filling in. Keeping a diagnosis private is a choice patients are entitled to make, and this article does not attribute a specific tumor type to him. What it can do is explain lymphoma, the cancer his death drew attention to, and in particular the larger of its two branches.

Lymphoma is not one disease

Lymphoma begins in the lymph system, the network of vessels, nodes, and fluid that carries immune cells around the body. NCI explains that lymph carries lymphocytes, the white blood cells that fight infection, and that lymphoma arises when those cells become cancerous.

The family splits in two. Hodgkin lymphoma is defined by a distinctive cell seen under the microscope. Everything else is non-Hodgkin lymphoma, and that "everything else" contains dozens of separate diseases.

Non-Hodgkin lymphoma is by far the larger group. SEER, the federal statistics program, lists about 79,320 new cases in the United States for 2026, or 3.8 percent of all new cancer diagnoses, along with roughly 19,970 deaths — both projected by the American Cancer Society. The median age at diagnosis is 68. It is the eighth leading cause of cancer death in the country. NCI reports that B-cell lymphomas make up around 85 percent of cases.

Indolent and aggressive, which sounds backward

The single most important division within non-Hodgkin lymphoma is between indolent and aggressive disease, and the terms do not mean what most people assume.

Indolent lymphomas grow slowly. NCI reports a relatively good prognosis, with median survival as long as 20 years, but adds that in advanced stages they are not curable. Follicular lymphoma is the main example, accounting for about 20 percent of all non-Hodgkin lymphoma and up to 70 percent of the indolent cases, with median survival ranging from 8 to 15 years.

Aggressive lymphomas grow fast and carry a worse short-term outlook. Yet NCI reports that more than 70 percent of patients are cured with intensive combination chemotherapy. Diffuse large B-cell lymphoma is the principal aggressive type.

So the slow one is often controlled for decades but rarely cured, while the fast one is dangerous and frequently curable. Getting the subtype right is therefore the whole game.

What it feels like

NCI advises checking with a doctor for any of these:

• Swelling of lymph nodes in the neck, underarm, groin, or abdomen.
• Fever for no known reason.
• Drenching night sweats.
• Feeling very tired.
• Weight loss for no known reason.
• Skin rash or itchy skin.
• Pain in the chest, abdomen, or bones for no known reason.

NCI notes that when fever, drenching night sweats, and weight loss occur together, the trio is known as B symptoms, and it carries specific weight in staging and treatment decisions.

Other symptoms depend on where the lymphoma forms, how large it is, and how fast it grows, which is why the presentation varies so widely between people.

When to get checked

Ask for an appointment if:

• A swollen node in the neck, armpit, or groin has lasted more than three or four weeks and is not shrinking, particularly if it is painless and rubbery.
• You have run a fever of 38 degrees Celsius, or 100.4 Fahrenheit, or higher with no infection anyone can find.
• Night sweats have been soaking your nightclothes or bedding.
• You have lost more than a tenth of your body weight over six months without trying.
• Your skin itches persistently and there is no rash to explain it.
• You have unexplained bone, chest, or abdominal pain lasting more than a couple of weeks.

Swollen nodes are usually caused by infection, and most people with these symptoms do not have lymphoma. There is no screening test for it, and NCI has no evidence-based screening or prevention summary, so symptoms are the only route to a diagnosis.

Getting an answer

Diagnosis rests on a biopsy. NCI says a lymph node biopsy is recommended whenever possible, though immunophenotypic data — which read the proteins on the cell surfaces, and are what separate the dozens of subtypes from one another — are sometimes enough when a fine-needle or core needle sample is preferred. NCI also says outside specimens should be reviewed by a hematopathologist experienced in lymphoma.

Blood work, imaging, and often a bone marrow examination follow, to establish extent. Staging uses the Lugano classification, running from stage I, a single lymphatic site, to stage IV, meaning widespread involvement beyond the lymph system.

Most people arrive already at an advanced stage. NCI notes that presentations commonly include non-adjacent lymph node groups, bone marrow, and liver. SEER's distribution reflects that: 37 percent of cases are stage IV at diagnosis, against 21 percent at stage I.

For follicular lymphoma, a scoring system called FLIPI combines five factors, namely age, LDH level, stage, hemoglobin, and the number of nodal areas involved. NCI reports 10-year survival of 67 percent for patients with none or one of those risk factors, against 36 percent for those with four or five.

Treatment, including doing nothing yet

For indolent lymphoma with no symptoms, NCI describes watchful waiting as a standard option. That means regular examinations and tests, with treatment held in reserve. Trials have not shown that treating slow-growing disease early helps, and treatment carries costs of its own.

When treatment is needed, options include rituximab, an antibody that targets a protein on B cells, given alone or combined with chemotherapy in the regimen known as R-CHOP. Targeted agents have expanded the choices. Early-stage disease may respond to radiation therapy alone.

What the numbers say

SEER reports five-year relative survival of 74.3 percent across all non-Hodgkin lymphoma for people diagnosed between 2016 and 2022. By stage it runs 87.6 percent for stage I, 79.7 percent for stage II, 74.0 percent for stage III, and 63.6 percent for stage IV.

The gap between stages is narrower here than in most cancers, because stage matters less than subtype. A slow disease found late and a fast disease found early sit in the same rows of that table.

These are group figures covering dozens of separate diseases over many years. They set context and nothing more. They describe no individual, and they cannot say anything about a person whose diagnosis was never made public.

Sources

• https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
• https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
• https://seer.cancer.gov/statfacts/html/nhl.html
• https://www.cancer.org/research/cancer-facts-statistics.html
• https://www.npr.org/2008/11/06/96689392/author-michael-crichton-dies-of-cancer